Novocure’s Optune receives positive coverage decision from Humana

Novocure, an oncology company based in Portsmouth, N.H., announced today that its portable, noninvasive brain tumor device Optune will now be covered by Humana, which becomes the ninth commercial payer in the U.S. to issue a positive coverage policy for the treatment.

That makes the device available to more than 107 million people across the United States, the company said in a press release.

Optune utilizes “tumor-treating fields”—alternating electric fields created within a tumor to prevent normal mitotic processes and cause cancer cell death—to deliver therapy to patients with newly diagnosed and recurrent glioblastoma.

Read the full press release here.